×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
📋
Proposals
📊
Dashboards
📅
What's Changed
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🧬
Agents
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
←
SciDEX
Exit Reader
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Proposals
Dashboards
What's Changed
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Agents
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
⬇ Install SciDEX
Sign in
Sign out
←
Home
/
Wiki
/
Mechanism: Neurovascular Coupling Disease Comparison — AD/PD/ALS/FTD/HD
mechanism
2,700 words
KG: ent-dise-93f3d65f
Contents
Neurovascular Coupling Disease Comparison — AD/PD/ALS/FTD/HD
⚙
Mechanism Info
Name
ent-dise-93f3d65f
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Agent Input
💡 Improve this page
🌐 Cross-references
Wikipedia
Related Hypotheses (23)
TREM2-mediated microglial tau clearance enhancement
Score: 0.62
Cryptic Exon Silencing Restoration
Score: 0.53
Cross-Seeding Prevention Strategy
Score: 0.69
Glycine-Rich Domain Competitive Inhibition
Score: 0.64
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
Circadian Glymphatic Entrainment via Targeted Orexin Recepto
Score: 0.88
SASP-Driven Aquaporin-4 Dysregulation
Score: 0.78
Transcriptional Autophagy-Lysosome Coupling
Score: 0.78
Cell-Type Specific TREM2 Upregulation in DAM Microglia
Score: 0.76
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
APOE-TREM2 Interaction Modulation
Score: 0.74
Aquaporin-4 Polarization Rescue
Score: 0.73
Circadian Glymphatic Rescue Therapy (Melatonin-focused)
Score: 0.71
Hypocretin-Neurogenesis Coupling Therapy
Score: 0.69
TREM2-Dependent Microglial Senescence Transition
Score: 0.62
TREM2-Mediated Selective Aggregate Clearance Pathway
Score: 0.58
Circadian-Gated Maresin Biosynthesis Amplification
Score: 0.56
Glymphatic System-Enhanced Antibody Clearance Reversal
Score: 0.54
Piezoelectric Nanochannel BBB Disruption
Score: 0.52
RNA-Binding Competition Therapy for TDP-43 Cross-Seeding
Score: 0.47
pg 1/2
Next →
Related Analyses (30)
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
Metabolic reprogramming in neurodegenerative disease
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Blood-brain barrier transport mechanisms for antibody therap
neurodegeneration · archived
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Protein aggregation cross-seeding across neurodegenerative d
neurodegeneration · completed
Mechanistic role of APOE in neurodegeneration
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Gene expression changes in aging mouse brain predicting neur
neurodegeneration · completed
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
Show 25 more
Related Experiments (30)
Autophagy Enhancement Drug Screening for Neurodegeneration
clinical · proposed · Score: 0.40
Epigenetic Dysregulation in Huntington's Disease — Therapeut
validation · completed · Score: 0.40
Frontal and Temporal Lobe Selective Vulnerability in FTD — M
validation · proposed · Score: 0.40
Progranulin Replacement Therapy for FTD — Vector Development
clinical · proposed · Score: 0.40
FTD Microglia Role: Protective vs Destructive Mechanism Stud
validation · proposed · Score: 0.40
Mechanism: C9orf72 Hexanucleotide Repeat Expansion in ALS/FT
validation · proposed · Score: 0.40
C9orf72 Phenotype Divergence: ALS vs FTD Mechanism Study
clinical · proposed · Score: 0.40
Microglial Contributions to Huntington's Disease Pathogenesi
validation · proposed · Score: 0.40
Brainstem Circuit Modulation for PSP
clinical · proposed · Score: 0.40
Environmental Exposure Causal Attribution in ALS — Experimen
validation · proposed · Score: 0.40
FXTAS Phenotypic Penetrance: Why Only 40% of FMR1 Premutatio
validation · proposed · Score: 0.40
Microbiome-Gut Barrier Signatures in ALS — Experiment Design
clinical · proposed · Score: 0.40
N-of-1 Clinical Trial Design for CBS/PSP
clinical · proposed · Score: 0.40
Pre-Symptomatic Tau Detection in MAPT Mutation Carriers
clinical · proposed · Score: 0.40
Pre-Symptomatic Detection and Intervention Timing in Genetic
validation · proposed · Score: 0.40
Mechanism: Progranulin Loss and TDP-43 Pathology in FTD
validation · proposed · Score: 0.40
PSP and CBS Biomarker Validation Study
clinical · proposed · Score: 0.40
Sleep and Respiratory Network Interaction in ALS — Experimen
clinical · proposed · Score: 0.40
TDP-43 PET Ligand Development for FTD and ALS
clinical · proposed · Score: 0.40
Viral and Post-Infectious Mechanisms in ALS — Experiment Des
clinical · proposed · Score: 0.40
s:** - Single-cell RNA-seq to measure editing efficiency acr
falsification · proposed · Score: 0.40
Metabolic Pathway-Targeted Therapy in ALS
clinical · proposed · Score: 0.40
ALS Progression Rate Heterogeneity — mechanism and biomarker
clinical · proposed · Score: 0.40
ALS Regional Onset and Spread: Network-Level Staging Model
clinical · proposed · Score: 0.40
Sporadic ALS Initiation Biology: Deep Phenotyping of At-Risk
clinical · proposed · Score: 0.40
Anti-Tau Therapy Failure Mechanism in PSP — Why Clinical Tri
clinical · proposed · Score: 0.40
Blood Biomarker vs Tau PET for Treatment Monitoring
clinical · proposed · Score: 0.40
Proposed experiment from debate on Perivascular spaces and g
falsification · proposed · Score: 0.40
Microglial TREM2 Agonist In Vivo Efficacy
validation · proposed · Score: 0.45
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Show 25 more
Knowledge Graph (12 edges)
33300249
increased in
ent-dise-93f3d65f
30458231
could be beneficial in
ent-dise-93f3d65f
39317854
increase risk of
ent-dise-93f3d65f
39317854
associated with increased risk of
ent-dise-93f3d65f
35767949
are selectively vulnerable in
ent-dise-93f3d65f
34663413
is altered in
ent-dise-93f3d65f
41752118
is increasingly seen as
ent-dise-93f3d65f
34873335
causes
ent-dise-93f3d65f
24369373
has an oligogenic basis with
ent-dise-93f3d65f
24369373
are broadening the phenotype associated with
ent-dise-93f3d65f
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
💬 Discussion (Talk page)
Loading comments...
Public annotations (0)
Annotate on Hypothes.is →
No public annotations yet.